Novel Pharmacogenomic Methodology for the Discovery of First-In-Class Mechanisms of Phenothiazine Derivatives to Delay and Rescue Alzheimer’s Disease Pathology and Extend Lifespan in C. elegans
ISEF · 2023 Biomedical and Health Sciences
Overview
Alzheimer’s Disease (AD) is the most common neurodegenerative disorder and the leading cause of death in the US. There are currently no effective drugs for this disease due to lack of understanding of disease pathogenesis and molecular targets. With expansion of human lifespan and aging population, AD is a public health emergency that urgently requires an effective drug. Phenotypic assay on model organism C. elegans was performed, in which phenothiazines were among the most protective drugs against Aß42-induced proteotoxicity measured by paralysis. Phenothiazines such as cyclophenazine and thioproperazine reduced TNF-a levels from microglia by up to 63.07%, a major brain immune cell responsible for neuroinflammation, and rescued paralysis by 80.41% in transgenic C. elegans. Prior to this research, it was undefined how phenothiazines can produce such anti-inflammatory, neuroprotective effects. Moreover, the molecular targets modulating the underlying therapeutic mechanism remained elusive due to limitations in conventional target identification techniques. This is the first study demonstrating a novel pharmacogenomic approach to uncover neuroprotective transcriptional mechanisms of phenothiazines, through correlational and gene network analyses. Phenothiazines comprehensively reversed the disease signature, possibly through epigenetic modulation by inhibiting CTBP2 with a Z-consensus score of -3.965, and PACS2 with a Kendall correlation of 1. This analysis also revealed numerous potential therapeutic avenues that target the disease genetic network. This technique can be applied to any assays in drug discovery labs, contributing to the overall understanding of AD by bridging the gap between genotype and phenotype, and nominating therapeutic targets and biomarkers.
Competition history
- ISEF 2023
Resources
Related projects
ISEF · 2024
Novel Drug Discovery Methodology Using Machine Learning for Gene Expression-Based Virtual Screening Predicts Novel Compounds To Reverse Alzheimer's Disease With Applications to Cancer and Longevity by Inhibiting CtBP2 Expression
ISEF · 2021
The Identification and Validation of Novel Targets and Pathways of Alzheimer's Disease Through Integrated System Approaches
ISEF · 2024
Identification of Novel Target Genes and ML-Based Drug Repurposing and Discovery for Alzheimer’s Disease in the Presence of Metabolic Comorbidities
ISEF · 2026
A Multi-Target Chronopharmacotherapy for the Inhibition and Clearance of Toxic Proteins in Alzheimer's Disease
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair